![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
PJ Emmerson, MR Liu, JH Woods and F Medzihradsky
Department of Pharmacology, University of Michigan Medical School, Ann Arbor.
The binding parameters of radiolabeled DAMGO (mu), DPDPE and pCl-DPDPE (delta) and 5 alpha, 7 alpha, 8 beta-N-methyl-N-[7-(1- pyrrolidinyl)-1- oxaspiro(4,5)dec-8-yl]benzeneacetamide (also known as U69593, kappa) and the affinity and selectivity profiles of various opioid agonists and antagonists at the three opioid receptor types were determined in membranes from brain cortex of rhesus monkey. Among the 10 opioids with established mu-selective actions, etonitazene inhibited the binding of [3H]DAMGO with a Ki of 0.02 nM (0.01 nM without sodium) and exhibited mu/delta and mu/kappa selectivities of 8800 and 11,650, respectively. DAMGO had a Ki of 1.23 nM and was about 500-fold more selective at mu receptors compared with delta and kappa sites. Other mu opioids with higher than 100-fold binding selectivity were fentanil and sufentanil. Highly selective delta opioids were DPDPE, deltorphin II and naltrindole. With the exception of N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH, all investigated putative delta opioids bound to delta sites with low Kis, i.e., 0.04 nM, 0.13 nM and 1.4 nM for naltrindole, (+/-)-4-[(alpha- R*)-alpha-((2S*,5R*)-4-allyl-2,5-dimethyl-1-piperazinyl) -3- hydroxybenzyl]-N,N-diethylbenzamide and DPDPE, respectively. In this series, the displacement of [3H]pCl-DPDPE yielded results similar to those obtained with [3H]DPDPE. With nanomolar Kis of 0.70, 0.89, 0.25 and 0.06, respectively, the highest kappa selectivity was displayed by (trans)-(+/-)-3,4-dichloro-N-methyl- N-[2-(1-pyrrolidinyl)- cyclohexyl]benzeneacetamide and U69593, followed by dynorphin 1-13 and norbinaltorphimine.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  Y.-J. Wang, Y.-M. Tao, F.-Y. Li, Y.-H. Wang, X.-J. Xu, J. Chen, Y.-L. Cao, Z.-Q. Chi, J. L. Neumeyer, A. Zhang, et al. Pharmacological Characterization of ATPM [(-)-3-Aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a Novel Mixed {kappa}-Agonist and {micro}-Agonist/-Antagonist That Attenuates Morphine Antinociceptive Tolerance and Heroin Self-Administration Behavior J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 306 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Ko and S. M. Husbands Effects of Atypical {kappa}-Opioid Receptor Agonists on Intrathecal Morphine-Induced Itch and Analgesia in Primates J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 193 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Lemberg, A. O. Siiskonen, V. K. Kontinen, J. T. Yli-Kauhaluoma, and E. A. Kalso Pharmacological Characterization of Noroxymorphone as a New Opioid for Spinal Analgesia Anesth. Analg., February 1, 2008; 106(2): 463 - 470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Poole, J. Deuchars, D. I. Lewis, and S. A. Deuchars Subdivision-Specific Responses of Neurons in the Nucleus of the Tractus Solitarius to Activation of Mu-Opioid Receptors in the Rat J Neurophysiol, November 1, 2007; 98(5): 3060 - 3071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Hawkinson, B. G. Szoke, A. W. Garofalo, D. S. Hom, H. Zhang, M. Dreyer, J. Y. Fukuda, L. Chen, B. Samant, S. Simmonds, et al. Pharmacological, Pharmacokinetic, and Primate Analgesic Efficacy Profile of the Novel Bradykinin B1 Receptor Antagonist ELN441958 J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 619 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-X. Li, G. L. Becker, J. R. Traynor, Z.-H. Gong, and C. P. France Thienorphine: Receptor Binding and Behavioral Effects in Rhesus Monkeys J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 227 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. H. Ko, H. Wei, J. H. Woods, and R. T. Kennedy Effects of Intrathecally Administered Nociceptin/Orphanin FQ in Monkeys: Behavioral and Mass Spectrometric Studies J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1257 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. H. Ko, M. F. Divin, H. Lee, J. H. Woods, and J. R. Traynor Differential in Vivo Potencies of Naltrexone and 6beta-Naltrexol in the Monkey J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 772 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. A. Khasabova, C. Harding-Rose, D. A. Simone, and V. S. Seybold Differential Effects of CB1 and Opioid Agonists on Two Populations of Adult Rat Dorsal Root Ganglion Neurons J. Neurosci., February 18, 2004; 24(7): 1744 - 1753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Stevenson, J. E. Folk, D. C. Linsenmayer, K. C. Rice, and S. S. Negus Opioid Interactions in Rhesus Monkeys: Effects of {delta} + {micro} and {delta} + {kappa} Agonists on Schedule-Controlled Responding and Thermal Nociception J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1054 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. H. Ko, H. Lee, C. Harrison, M. J. Clark, H. F. Song, N. N. Naughton, J. H. Woods, and J. R. Traynor Studies of {micro}-, {kappa}-, and {delta}-Opioid Receptor Density and G Protein Activation in the Cortex and Thalamus of Monkeys J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 179 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. Cosgrove and M. E. Carroll Effects of Bremazocine on Self-Administration of Smoked Cocaine Base and Orally Delivered Ethanol, Phencyclidine, Saccharin, and Food in Rhesus Monkeys: A Behavioral Economic Analysis J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 993 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Newman, S. S. Sands, D. R. Wallace, and C. W. Stevens Characterization of {micro}, kappa , and delta Opioid Binding in Amphibian Whole Brain Tissue Homogenates J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 364 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Butelman, M. C. H. Ko, J. R. Traynor, J. A. Vivian, M.-J. Kreek, and J. H. Woods GR89,696: A Potent kappa -Opioid Agonist with Subtype Selectivity in Rhesus Monkeys J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1049 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Cavun, G. E. Resch, A. D. Evec, M. M. Rapacon-Baker, and W. R. Millington Blockade of Delta Opioid Receptors in the Ventrolateral Periaqueductal Gray Region Inhibits the Fall in Arterial Pressure Evoked by Hemorrhage J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 612 - 619. [Abstract] [Full Text]
|
|
|
|
|
|
S. S. Negus and N. K. Mello Opioid Antinociception in Ovariectomized Monkeys: Comparison with Antinociception in Males and Effects of Estradiol Replacement J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1132 - 1140. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. M. Quock, T. H. Burkey, E. Varga, Y. Hosohata, K. Hosohata, S. M. Cowell, C. A. Slate, F. J. Ehlert, W. R. Roeske, and H. I. Yamamura The delta -Opioid Receptor: Molecular Pharmacology, Signal Transduction, and the Determination of Drug Efficacy Pharmacol. Rev., September 1, 1999; 51(3): 503 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Mason, F. R. Salvato, L. D. Williams, E. C. Ritvo, and R. B. Cutler A Double-blind, Placebo-Controlled Study of Oral Nalmefene for Alcohol Dependence Arch Gen Psychiatry, August 1, 1999; 56(8): 719 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Ang, R. J. McRitchie, J. B. Minson, I. J. Llewellyn-Smith, P. M. Pilowsky, J. P. Chalmers, and L. F. Arnolda Activation of spinal opioid receptors contributes to hypotension after hemorrhage in conscious rats Am J Physiol Heart Circ Physiol, May 1, 1999; 276(5): H1552 - H1558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Muller, S. Hallermann, and D. Swandulla Opioidergic Modulation of Voltage-Activated K+ Currents in Magnocellular Neurons of the Supraoptic Nucleus in Rat J Neurophysiol, April 1, 1999; 81(4): 1617 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Remmers, M. J. Clark, A. Mansour, H. Akil, J. H. Woods, and F. Medzihradsky Opioid Efficacy in a C6 Glioma Cell Line Stably Expressing the Human Kappa Opioid Receptor J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 827 - 833. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Kreek, J. Schluger, L. Borg, M. Gunduz, and A. Ho Dynorphin A1-13 Causes Elevation of Serum Levels of Prolactin Through an Opioid Receptor Mechanism in Humans: Gender Differences and Implications for Modulation of Dopaminergic Tone in the Treatment of Addictions J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 260 - 269. [Abstract] [Full Text]
|
|
|
|
|
|
N. K. Mello and S. S. Negus Effects of Kappa Opioid Agonists on Cocaine- and Food-Maintained Responding by Rhesus Monkeys J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 812 - 824. [Abstract] [Full Text]
|
|
|
|
|
|
L. He and N. M. Lee Delta Opioid Receptor Enhancement of Mu Opioid Receptor-Induced Antinociception in Spinal Cord J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1181 - 1186. [Abstract] [Full Text]
|
|
|
|
|
|
D. E. Selley, Q. Liu, and S. R. Childers Signal Transduction Correlates of Mu Opioid Agonist Intrinsic Efficacy: Receptor-Stimulated [35S]GTPgamma S Binding in mMOR-CHO Cells and Rat Thalamus J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 496 - 505. [Abstract] [Full Text]
|
|
|
|
|
|
M.-C. Ko, E. R. Butelman, J. R. Traynor, and J. H. Woods Differentiation of Kappa Opioid Agonist-Induced Antinociception by Naltrexone Apparent pA2 Analysis in Rhesus Monkeys, J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 518 - 526. [Abstract] [Full Text]
|
|
|
|
|
|
E. R. Butelman, M.-C. Ko, K. Sobczyk-Kojiro, H. I. Mosberg, B. V. Bemmel, G. Zernig, and J. H. Woods Kappa-Opioid Receptor Binding Populations in Rhesus Monkey Brain: Relationship to an Assay of Thermal Antinociception J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 595 - 601. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Clark, P. J. Emmerson, A. Mansour, H. Akil, J. H. Woods, P. S. Portoghese, A. E. Remmers, and F. Medzihradsky Opioid Efficacy in a C6 Glioma Cell Line Stably Expressing the Delta Opioid Receptor J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 501 - 510. [Abstract] [Full Text]
|
|
|
|
|
|
J. K. Staley, R. B. Rothman, K. C. Rice, J. Partilla, and D. C. Mash kappa 2 Opioid Receptors in Limbic Areas of the Human Brain Are Upregulated by Cocaine in Fatal Overdose Victims J. Neurosci., November 1, 1997; 17(21): 8225 - 8233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Massotte, L. Baroche, F. Simonin, L. Yu, B. Kieffer, and F. Pattus Characterization of delta , kappa , and µ Human Opioid Receptors Overexpressed in Baculovirus-infected Insect Cells J. Biol. Chem., August 8, 1997; 272(32): 19987 - 19992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Negus, N. K. Mello, P. S. Portoghese, and C.-E. Lin Effects of Kappa Opioids on Cocaine Self-Administration by Rhesus Monkeys J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 44 - 55. [Abstract] [Full Text]
|
|
|
|
|
|
M. K. Greenwald, M. L. Stitzer, and K. A. Haberny J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1154 - 1163. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
